Abstract. The 
31%. These data show that ketoconazole induce marked changes on corticotrope morphology and ACTH secretion in pituitary cells obtained from patients with Nelson's syndrome.
Ketoconazole, an imidazole derivative used for its antimycotic action, inhibits ergosterole synthesis in fungi. In humans, as well as inhibiting choleste¬ rol synthesis, it inhibits steroid synthesis in the suprarenal gland (glucocorticoids, mineralocorticoids and androgens) (1) and in the gonads (androgens and estrogens) (2) by inhibition of cytochrome P-450 dependent enzymes (llß-hydroxylase, 17-20 lyase, [20] [21] [22] desmolase, etc) (3) .
In Cushing's syndrome, ketoconazole has proved to normalize glucocorticoid function, both in short-term and in chronic treatments (4) . A com¬ pensatory increase in the level of ACTH has also been reported throughout chronic treatment of Cushing's syndrome with ketoconazole (5) . There is also evidence of a decrease of ACTH, as well as of cortisol, during long-term treatment of Cushing's syndrome (6) .
In vitro studies with rat pituitary cells and human pituitary adenoma cells show that ketoco¬ nazole has no direct effects on the secretion of ACTH (7, 8 (Fig. 2) . After 10 umol/1 of ketoconazole cis¬ ternae of ergastoplasm were less obvious in corti¬ cotropic cells (Fig. 3) 
